OncoGenex Pharmaceuticals (OGXI) has been under a strong bear grip, hence the stock is down -13.91% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.69% in the past 1 week. The stock has risen by 1.12% in the past week indicating that the buyers are active at lower levels, but the stock is down -11.77% in the past 4 weeks.
OncoGenex Pharmaceuticals (NASDAQ:OGXI): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.88 and $0.85 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.90, notching a gain of 2.27% for the day. The total traded volume was 109,165 . The stock had closed at $0.88 on the previous day.
The stock has recorded a 20-day Moving Average of 3.26% and the 50-Day Moving Average is 9.79%. OncoGenex Pharmaceuticals, Inc. has dropped 5.26% during the last 3-month period . Year-to-Date the stock performance stands at -25.62%.
OncoGenex Pharmaceuticals (OGXI) : Average target price received by OncoGenex Pharmaceuticals (OGXI) is $3.5 with an expected standard deviation of $0.71. The most aggressive target on the stock is $4, whereas the most downbeat target is $3. 2 financial analysts are currently covering the stock.
OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company has three product candidates in its pipeline: custirsen, apatorsen and OGX-225. Of the product candidates in its pipeline, custirsen and apatorsen are clinical-stage assets being evaluated in two Phase III studies and five Phase II studies. These product candidates focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments.